Compare Kingsoft Cloud Holdings Limited (KC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kingsoft Cloud Holdings Limited vs Merck & Co., Inc. — how do they compare? Kingsoft Cloud Holdings Limited trades at $9.26 (market cap $2.71B), while Merck & Co., Inc. trades at $145.83 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 129.6× Kingsoft Cloud Holdings Limited's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kingsoft Cloud Holdings Limited for 12 Days and Merck & Co., Inc. for 98 Days on average.
| KC | MRK | |
|---|---|---|
Market Cap | $2.71B | $351.28B |
Volume | 1,993,765 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $18.21 | $156.43 |
52-Week Low | $8.58 | $82.49 |
Typical Hold Time | 12 Days | 98 Days |
Enterprise Value | $3.03B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kingsoft Cloud (KC) trades at $9.26, up 0.27% with bearish technical signals but strong analyst support. The company shows improving fundamentals with Q2 2026 revenue growth of 30.8% year-over-year and three consecutive earnings beats. While still reporting net losses, gross margins improved significantly and AI cloud services are emerging as a key growth driver, with billings surging 82% year-over-year.
KC presents a compelling turnaround story with 70% analyst buy ratings and 60% upside potential, though risks include persistent losses, competitive pressures, and technical weakness. The AI cloud partnership with Xiaomi positions the stock for growth, but investors should weigh the fundamental improvements against the current bearish technical setup.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
